China Shineway Pharmaceutical Group Limited stock analysis
Want to see HK:2877 full AI Analyst Report?
China Shineway Pharmaceutical Group Limited (2877) Stock Price & Analysis
2877 Stock Chart & Stats
- Day’s Range
- HKD 7.57 - HKD 7.64
- 52-Week Range
- HKD 7.12 - HKD 10.47
- Previous Close
- HKD 7.63
- Volume
- N/A
- Average Volume (3M)
- 995.91K
- Market Cap
- HKD 5.74B
- Enterprise Value
- -HKD 2.78B
- Total Cash (Recent Filing)
- HKD 7.54B
- Total Debt (Recent Filing)
- HKD 312.23M
- Price to Earnings (P/E)
- 6.2
- Beta
- 0.47
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Oct 02, 2026
- Dividend Yield
- 16.46%
Bulls Say, Bears Say
Bulls Say
High Profitability
Sustained high gross and operating margins indicate strong product economics in the company’s proprietary TCM portfolio. This profitability provides resilience against cost pressure and supports continued investment in research, manufacturing quality, hospital access, and distribution over the coming quarters.
Very Low Leverage
Minimal leverage materially limits interest burdens, refinancing exposure, and balance-sheet stress during weaker demand periods. The conservative capital structure preserves financial flexibility to fund operations, product development, and shareholder distributions without relying heavily on external borrowing.
Positive Cash Generation
Consistently positive free cash flow indicates that reported profitability is being converted into internally generated funds. Stronger 2025 cash generation can support working capital, research and development, manufacturing investment, and distributions while reducing dependence on debt financing.
Bears Say
Revenue Contraction
The sustained weakening in revenue momentum signals pressure on product volumes, pricing, or mix across the TCM portfolio. If contraction persists, lower operating scale could reduce the company’s ability to absorb fixed manufacturing, quality-control, and commercial costs.
Margin Softening
Although margins remain healthy, the decline from the 2023 peak suggests that the company’s earnings conversion is not fully stable. Continued pressure from product mix, pricing, or operating costs could reduce the benefit of its otherwise strong gross-margin structure over the next several quarters.
Volatile Cash-Flow Growth
Year-to-year volatility in free cash flow makes the timing and reliability of internally funded investment less predictable. Even with positive cash generation, uneven conversion can complicate planning for research, production capacity, commercial spending, and shareholder returns.
China Shineway Pharmaceutical Group Limited News
China Shineway Pharmaceutical Declares Special Interim Dividend and Sets Book Closure Dates
China Shineway Pharmaceutical Group Limited ( ($HK:2877) ) has issued an announcement. China Shineway Pharmaceutical Group Limited has declared a special interim dividend of RMB0.85 per ordinary share, payable in
2877 FAQ
What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?
What is China Shineway Pharmaceutical Group Limited’s market cap?
When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?
How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?
Is China Shineway Pharmaceutical Group Limited overvalued?
Does China Shineway Pharmaceutical Group Limited pay dividends?
What is China Shineway Pharmaceutical Group Limited’s EPS estimate?
How many shares outstanding does China Shineway Pharmaceutical Group Limited have?
What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?
What is the TipRanks Smart Score and how is it calculated?
China Shineway Pharmaceutical Group Limited Stock Smart Score
Company Description
China Shineway Pharmaceutical Group Limited
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Zhenjiang Li
- Employees
- 2,656
- Website
- www.shineway.com.hk
- Address
- Luan Cheng District, Shijiazhuang, HE, 051430, CN
China Shineway Pharmaceutical Group Limited (2877) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 10 | 0 | 2 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| HK:3933The United Laboratories International Holdings | ||
| HK:0570China Traditional Chinese Medicine Holdings Co | ||
| HK:2633Jacobson Pharma Corporation Limited | ||
| HK:0512Grand Pharmaceutical Group Limited | ||
| HK:0719Shandong Xinhua Pharmaceutical Company Limited Class H |











